Published in Crit Care on January 06, 2005
Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev (2008) 17.77
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care (2006) 3.35
Polymyxins revisited. Clin Microbiol Rev (2008) 3.16
Colistin in the 21st century. Curr Opin Infect Dis (2009) 1.93
Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations. Lung India (2012) 1.40
Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother (2008) 1.15
The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res (2006) 1.14
Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria. Microbiol Insights (2016) 1.13
Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob Agents Chemother (2010) 1.13
Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin. Antimicrob Agents Chemother (2014) 1.03
Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis (2008) 1.02
Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol (2008) 1.02
Acinetobacter pneumonia: a review. MedGenMed (2007) 0.99
Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care (2005) 0.92
Differences in biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients. Int J Antimicrob Agents (2011) 0.92
A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis (2011) 0.90
Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii. Yonsei Med J (2014) 0.85
Expert synthesis of the literature to support critical care decision making. J Med Libr Assoc (2006) 0.84
Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study. BMC Anesthesiol (2013) 0.82
A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema. Proc Natl Acad Sci U S A (2010) 0.81
Prognostic differences between VAP from Acinetobacter baumanii and VAP from other microorganisms. Transl Med UniSa (2012) 0.80
Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature review. J Res Pharm Pract (2015) 0.80
The significance of different formulations of aerosolized colistin. Crit Care (2005) 0.76
Inhaled Antibiotics for Gram-Negative Respiratory Infections. Clin Microbiol Rev (2016) 0.76
Year in review 2005: Critical Care--respirology: mechanical ventilation, infection, monitoring, and education. Crit Care (2006) 0.75
Year in review in Critical Care, 2003 and 2004: respirology and critical care. Crit Care (2005) 0.75
Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation. J Pharm Sci (2012) 0.75
Effect of nebulized colistin on the ventilator circuit: a prospective pilot case- control study from a single cancer center. Mediterr J Hematol Infect Dis (2015) 0.75
Pulmonary Pharmacokinetics of Colistin Following Administration of Dry Powder Aerosols in Rats. Antimicrob Agents Chemother (2017) 0.75
Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic/Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Antimicrob Agents Chemother (2017) 0.75
Ventilator-associated pneumonia. Am J Respir Crit Care Med (2002) 9.63
Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis (1999) 5.90
Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect (2005) 3.39
Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis (2003) 3.37
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet (1991) 3.26
Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother (1987) 2.00
Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis (2003) 1.89
Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet (1985) 1.86
The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med (2001) 1.61
Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med (1975) 1.39
Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med (2000) 1.37
Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child (2001) 1.02
Nebulized colistin causes chest tightness in adults with cystic fibrosis. Respir Med (1994) 1.00
Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol (1997) 0.95
Evaluation of sodium colistimethate aerosol in gram-negative infections of the respiratory tract. J Clin Pharmacol J New Drugs (1970) 0.94
Nebulizer performance: AFLM study. Association Française de Lutte contre la Mucoviscidose. Respiration (1995) 0.93
Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm (2002) 0.91
Polymyxin inhalation therapeutic hazard. Ann Intern Med (1971) 0.89
Ultra-sonic nebulizers as a potential source of methicillin-resistant Staphylococcus aureus causing an outbreak in a university tertiary care hospital. J Hosp Infect (2003) 0.88
Clinical relevance of Acinetobacter baumannii ventilator-associated pneumonia. Crit Care Med (2003) 0.84
Evaluation of two commercial jet nebulisers and three compressors for the nebulisation of antibiotics. Arch Dis Child (1994) 0.84
[Nosocomial infection/colonization of the respiratory tract caused by Acinetobacter baumannii in an Internal Medicine ward]. An Med Interna (2002) 0.84
Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation (1997) 0.81
[CLINICAL OBSERVATIONS ON THE ACTIVITY OF AEROSOL COLIMYCIN AND OF ENDOBRONCHIAL INSTILLATIONS OF COLIMYCIN IN PATIENTS WITH PULMONARY SUPPURATIONS]. Minerva Med (1963) 0.81
Bacterial contamination potential of sterile, prefilled humidifiers and nebulizer reservoirs. Heart Lung (1980) 0.79
Nebulized colistin (polymyxin E) for AIDS-associated Pseudomonas aeruginosa pneumonia. Int J STD AIDS (1992) 0.79
Prolonged efficiency of secondary prophylaxis with colistin aerosols for respiratory infection due to Pseudomonas aeruginosa in patients infected with human immunodeficiency virus. Clin Infect Dis (1996) 0.79
Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis (2005) 6.60
A bibliometric analysis of global research production in respiratory medicine. Chest (2005) 4.15
Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J (2008) 3.60
Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med (2010) 3.43
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care (2006) 3.35
Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol (2009) 3.27
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis (2008) 2.87
Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother (2007) 2.79
Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis (2010) 2.60
Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med (2007) 2.58
Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother (2005) 2.47
Comparison of amount of biomedical research originating from the European Union and the United States. BMJ (2005) 2.42
Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol (2007) 2.35
Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis (2014) 2.29
Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg (2008) 2.10
β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis (2011) 2.03
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother (2012) 2.01
Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother (2008) 1.98
Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis (2008) 1.91
Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis (2005) 1.89
Estimates of global production in cardiovascular diseases research. Int J Cardiol (2005) 1.87
Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect (2012) 1.84
Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol (2008) 1.77
Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLoS Negl Trop Dis (2008) 1.75
Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis (2005) 1.74
Unique author identification number in scientific databases: a suggestion. PLoS Med (2006) 1.73
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis (2005) 1.70
Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med (2008) 1.69
Frequency, prevention, outcome and treatment of ventilator-associated tracheobronchitis: systematic review and meta-analysis. Respir Med (2010) 1.67
Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol (2005) 1.60
Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ (2008) 1.60
Worldwide prevalence of head lice. Emerg Infect Dis (2008) 1.58
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother (2008) 1.56
Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother (2011) 1.55
Impact of patient position on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. J Crit Care (2009) 1.55
Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest (2007) 1.55
Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care (2011) 1.54
Prevalence of hepatitis B, hepatitis C, and HIV infections among patients in a psychiatric hospital in Greece. Psychiatr Serv (2009) 1.54
Research contribution of different world regions in the top 50 biomedical journals (1995-2002). FASEB J (2006) 1.54
Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis (2006) 1.52
Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ (2008) 1.51
Impact of passive humidification on clinical outcomes of mechanically ventilated patients: a meta-analysis of randomized controlled trials. Crit Care Med (2007) 1.50
Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J (2007) 1.49
Bowel cleansing before bowel surgery: major discordance between evidence and practice. J Gastrointest Surg (2008) 1.45
Do we still need the aminoglycosides? Int J Antimicrob Agents (2008) 1.45
World databases of summaries of articles in the biomedical fields. Arch Intern Med (2007) 1.43
Effectiveness and safety of short-course vs long-course antibiotic therapy for group a beta hemolytic streptococcal tonsillopharyngitis: a meta-analysis of randomized trials. Mayo Clin Proc (2008) 1.42
Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis (2005) 1.40
Non-physicians may reach correct diagnoses by using Google: a pilot study. Swiss Med Wkly (2008) 1.40
Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: a meta-analysis of randomized controlled trials. Spine (Phila Pa 1976) (2008) 1.40
Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother (2006) 1.39
Worldwide trends in quantity and quality of published articles in the field of infectious diseases. BMC Infect Dis (2005) 1.39
From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J (2005) 1.39
Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother (2009) 1.38
Pain and a purple lesion. Am J Med (2006) 1.38
Tuberculosis of the oral cavity: a systematic review. Eur J Oral Sci (2010) 1.37
Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents (2005) 1.36
Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents (2009) 1.35
Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol (2009) 1.34
Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther (2007) 1.34
Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis (2005) 1.33
Age distribution of cases of 2009 (H1N1) pandemic influenza in comparison with seasonal influenza. PLoS One (2011) 1.33
Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents (2012) 1.32
Human infections associated with wild birds. J Infect (2007) 1.29
A bibliometric analysis in the fields of preventive medicine, occupational and environmental medicine, epidemiology, and public health. BMC Public Health (2006) 1.27
Mapping health literacy research in the European Union: a bibliometric analysis. PLoS One (2008) 1.25
Infections related to airway stenting: a systematic review. Respiration (2009) 1.21
Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother (2007) 1.21
Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Med (2011) 1.20
Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc (2005) 1.20
Probiotics for the prevention of respiratory tract infections: a systematic review. Int J Antimicrob Agents (2009) 1.19
Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. Ann Allergy Asthma Immunol (2008) 1.18
Treatment of Acinetobacter infections. Expert Opin Pharmacother (2010) 1.18
Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med (2007) 1.17
Frequency, characteristics, and predictors of microbiologically documented nosocomial infections after cardiac surgery. Eur J Cardiothorac Surg (2006) 1.17
The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res (2006) 1.14
Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol (2010) 1.14
Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int J Antimicrob Agents (2008) 1.13
Outcomes after medical and surgical treatment of diverticulitis: a systematic review of the available evidence. J Gastroenterol Hepatol (2007) 1.12
Do psychological variables affect early surgical recovery? PLoS One (2011) 1.11
Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS One (2012) 1.10
Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime. J Infect (2007) 1.09
Health literacy research in Europe: a snapshot. Eur J Public Health (2005) 1.08
Insights into infectious disease in the era of Hippocrates. Int J Infect Dis (2008) 1.07
Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options. Curr Opin Investig Drugs (2008) 1.07
Meta-analyses on behavioral interventions to reduce the risk of transmission of HIV. Infect Dis Clin North Am (2009) 1.07
World Wide Web resources on control of nosocomial infections. Crit Care (2007) 1.07
Outcome of antimicrobial therapy in documented biofilm-associated infections: a review of the available clinical evidence. Drugs (2009) 1.07
Colistin and polymyxin B in critical care. Crit Care Clin (2008) 1.06
Free internal medicine case-based education through the World Wide Web: how, where, and with what? Mayo Clin Proc (2007) 1.06
Temporal trends in the impact factor of European versus USA biomedical journals. PLoS One (2011) 1.06
Polymyxins: a review of the current status including recent developments. Ann Acad Med Singapore (2008) 1.06
Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. Int J Infect Dis (2012) 1.05
Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. J Infect (2005) 1.05